RS55560B1 - 4-(8-metoksi-1-((1-metoksipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]hinolin-7-il)-3,5-dimetilizoksazol i njegova upotreba kao inhibitora bromodomena - Google Patents

4-(8-metoksi-1-((1-metoksipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]hinolin-7-il)-3,5-dimetilizoksazol i njegova upotreba kao inhibitora bromodomena

Info

Publication number
RS55560B1
RS55560B1 RS20170014A RSP20170014A RS55560B1 RS 55560 B1 RS55560 B1 RS 55560B1 RS 20170014 A RS20170014 A RS 20170014A RS P20170014 A RSP20170014 A RS P20170014A RS 55560 B1 RS55560 B1 RS 55560B1
Authority
RS
Serbia
Prior art keywords
dimethylisoxazole
methoxypropan
quinolin
imidazo
pyran
Prior art date
Application number
RS20170014A
Other languages
English (en)
Serbian (sr)
Inventor
Emmanuel Hubert Demont
Katherine Louise Jones
Robert J Watson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of RS55560B1 publication Critical patent/RS55560B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20170014A 2011-08-17 2012-08-15 4-(8-metoksi-1-((1-metoksipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]hinolin-7-il)-3,5-dimetilizoksazol i njegova upotreba kao inhibitora bromodomena RS55560B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1114103.3A GB201114103D0 (en) 2011-08-17 2011-08-17 Novel compounds
PCT/EP2012/065918 WO2013024104A1 (en) 2011-08-17 2012-08-15 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
EP12748028.3A EP2744809B1 (en) 2011-08-17 2012-08-15 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Publications (1)

Publication Number Publication Date
RS55560B1 true RS55560B1 (sr) 2017-05-31

Family

ID=44764570

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170014A RS55560B1 (sr) 2011-08-17 2012-08-15 4-(8-metoksi-1-((1-metoksipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]hinolin-7-il)-3,5-dimetilizoksazol i njegova upotreba kao inhibitora bromodomena

Country Status (38)

Country Link
US (4) US9067936B2 (enEXAMPLES)
EP (2) EP3150601A1 (enEXAMPLES)
JP (1) JP6059723B2 (enEXAMPLES)
KR (1) KR20140064878A (enEXAMPLES)
CN (1) CN103889984B (enEXAMPLES)
AR (1) AR087545A1 (enEXAMPLES)
AU (1) AU2012296914B2 (enEXAMPLES)
BR (1) BR112014003681A8 (enEXAMPLES)
CA (1) CA2843537A1 (enEXAMPLES)
CL (1) CL2014000365A1 (enEXAMPLES)
CO (1) CO6862151A2 (enEXAMPLES)
CR (1) CR20140076A (enEXAMPLES)
CY (1) CY1118370T1 (enEXAMPLES)
DK (1) DK2744809T3 (enEXAMPLES)
DO (1) DOP2014000031A (enEXAMPLES)
EA (1) EA023374B1 (enEXAMPLES)
ES (1) ES2609857T3 (enEXAMPLES)
GB (1) GB201114103D0 (enEXAMPLES)
HR (1) HRP20161674T1 (enEXAMPLES)
HU (1) HUE030106T2 (enEXAMPLES)
IL (1) IL230489A (enEXAMPLES)
IN (1) IN2014CN00568A (enEXAMPLES)
JO (1) JO3187B1 (enEXAMPLES)
LT (1) LT2744809T (enEXAMPLES)
ME (1) ME02589B (enEXAMPLES)
MX (1) MX350597B (enEXAMPLES)
MY (1) MY170729A (enEXAMPLES)
PE (1) PE20141406A1 (enEXAMPLES)
PH (1) PH12014500379A1 (enEXAMPLES)
PL (1) PL2744809T3 (enEXAMPLES)
PT (1) PT2744809T (enEXAMPLES)
RS (1) RS55560B1 (enEXAMPLES)
SI (1) SI2744809T1 (enEXAMPLES)
SM (2) SMT201700005T1 (enEXAMPLES)
TW (1) TWI558704B (enEXAMPLES)
UA (1) UA110838C2 (enEXAMPLES)
UY (1) UY34264A (enEXAMPLES)
WO (1) WO2013024104A1 (enEXAMPLES)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
WO2014164780A1 (en) 2013-03-11 2014-10-09 Abbvie Inc. Fused tetracyclic bromodomain inhibitors
MX2015012005A (es) 2013-03-11 2016-04-04 Abbvie Inc Inhibidores de bromodominio.
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
NZ754629A (en) 2013-06-21 2021-07-30 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EA201690087A1 (ru) 2013-07-31 2016-08-31 Зенит Эпидженетикс Корп. Новые квиназолиноны как ингибиторы бромодомена
WO2015049629A1 (en) * 2013-10-01 2015-04-09 Piramal Enterprises Limited Imidazoquinoline compounds as bromodomain inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CN107074861A (zh) 2014-02-28 2017-08-18 密执安大学评议会 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物
LT3674302T (lt) 2014-04-23 2023-06-12 Incyte Holdings Corporation 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai kaip bet baltymų inhibitoriai
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
EP3253756B1 (en) 2015-02-03 2021-09-22 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016186453A1 (en) * 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
JP6912039B2 (ja) 2015-08-12 2021-07-28 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
US11548899B2 (en) 2016-02-15 2023-01-10 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
RU2743432C2 (ru) 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
EP3442976B1 (en) 2016-04-12 2022-07-20 The Regents of The University of Michigan Bet protein degraders
US10189832B2 (en) 2016-06-20 2019-01-29 Incyte Corporation Crystalline solid forms of a BET inhibitor
AU2017326171B2 (en) 2016-09-13 2021-12-09 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
JP7035027B2 (ja) 2016-09-13 2022-03-14 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
CN108033957A (zh) * 2018-01-09 2018-05-15 中国药科大学 一种喹啉类BET bromodomain抑制剂及其制备方法和用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022132049A1 (en) * 2020-12-17 2022-06-23 National University Of Singapore Treating cancers using bet inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
EP1687305B1 (en) 2003-11-21 2008-07-09 Novartis AG 1h-imidazoquinoline derivatives as protein kinase inhibitors
EP1845988A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
BRPI0616338A2 (pt) 2005-09-23 2011-06-14 Coley Pharm Group Inc mÉtodo para 1h-imidazo[4,5-c] piridinas e anÁlogos da mesma
CN101330916A (zh) 2005-12-16 2008-12-24 科勒制药集团公司 经取代的咪唑并喹啉、咪唑并萘啶和咪唑并吡啶、其组合物及其方法
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
EP3050885B1 (en) * 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
EP2744809B1 (en) 2016-10-12
GB201114103D0 (en) 2011-09-28
SMT201700005T1 (it) 2017-03-08
CN103889984A (zh) 2014-06-25
JP6059723B2 (ja) 2017-01-11
EP3150601A1 (en) 2017-04-05
CO6862151A2 (es) 2014-02-10
SI2744809T1 (sl) 2017-01-31
CN103889984B (zh) 2016-01-13
PE20141406A1 (es) 2014-10-25
SMT201700005B (it) 2017-03-08
UY34264A (es) 2013-04-05
KR20140064878A (ko) 2014-05-28
US20170157113A1 (en) 2017-06-08
US9416130B2 (en) 2016-08-16
HRP20161674T1 (hr) 2017-01-27
BR112014003681A2 (pt) 2017-03-01
US20150315184A1 (en) 2015-11-05
ME02589B (me) 2017-06-20
IL230489A (en) 2016-07-31
AU2012296914A1 (en) 2014-02-13
US20140171462A1 (en) 2014-06-19
MX350597B (es) 2017-09-11
TW201323424A (zh) 2013-06-16
EP2744809A1 (en) 2014-06-25
MX2014001834A (es) 2014-02-27
LT2744809T (lt) 2016-12-27
IL230489A0 (en) 2014-03-31
EA201490200A1 (ru) 2014-07-30
WO2013024104A1 (en) 2013-02-21
US9067936B2 (en) 2015-06-30
JO3187B1 (ar) 2018-03-08
CA2843537A1 (en) 2013-02-21
PH12014500379A1 (en) 2021-07-12
DOP2014000031A (es) 2014-06-01
JP2014521735A (ja) 2014-08-28
US9610284B2 (en) 2017-04-04
TWI558704B (zh) 2016-11-21
DK2744809T3 (en) 2017-01-23
US20160317529A1 (en) 2016-11-03
CY1118370T1 (el) 2017-06-28
PL2744809T3 (pl) 2017-08-31
ES2609857T3 (es) 2017-04-24
IN2014CN00568A (enEXAMPLES) 2015-04-03
AU2012296914B2 (en) 2016-03-03
EA023374B1 (ru) 2016-05-31
UA110838C2 (uk) 2016-02-25
CR20140076A (es) 2014-03-19
AR087545A1 (es) 2014-04-03
CL2014000365A1 (es) 2014-07-11
PT2744809T (pt) 2017-01-06
MY170729A (en) 2019-08-27
NZ620263A (en) 2016-04-29
HUE030106T2 (en) 2017-04-28
US9861627B2 (en) 2018-01-09
BR112014003681A8 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
SMT201700005T1 (it) 4-(8-metossi-1-((1-metossipropan-2-il)-2-(tetraidro-2h-piran-4-il)-1h-imidazo[4,5- c]chinolin-7-il)-3,5-dimetilisossazolo e suo uso come inibitore di bromodominio
PL2663564T3 (pl) Związek imidazo[4,5-c]chinolin-2-onu i jego zastosowanie jako podwójnego inhibitora kinazy pi3/mtor
IL228642A0 (en) Combinations of Akt inhibitor compounds and Bemorphanib, and methods of use
AP4017A (en) Substituted triazolopyridines and their use as ttk inhibitors
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
ZA201205730B (en) Certain triazolopyridines and triazolopyrazines,compositions thereof and methods of use therefor
EP2841068B8 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
EP2740729A4 (en) QUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND, AND USE OF THE DERIVATIVE IN THE PREPARATION OF A MEDICAMENT
BR112013012175A2 (pt) combinação, coadministração, uso e método
IL232712A (en) [1, 2, 4] Triazulophyridines and their use as phosphodiesterase inhibitors
ZA201205273B (en) Methods and compositions for providing protective immunity in the elderly
EP2610257A4 (en) DIIMIDED DERIVATIVE OF BERBAMINE, MANUFACTURING METHOD AND ITS USE
ZA201200562B (en) New bicyclic dioxanes,their preparation and their use as fragrant compounds
HK1193411A (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
HK1193981A (en) Autophagy inducing compound and use thereof
AU2010905441A0 (en) Methods For Forming Miniemulsions And Use Thereof For Delivering Bioactive Agents
AU2010903588A0 (en) Flavonoid compounds, and methods of use thereof
HK1177735A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor